Persistence of long-term COVID-19 sequelae in patients with cancer : An analysis from the OnCovid registry
Copyright © 2022 Elsevier Ltd. All rights reserved..
INTRODUCTION: A significant proportion of patients with cancer who recover from Coronavirus Disease 2019 (COVID-19) may experience COVID-19 sequelae in the early post-infection phase, which negatively affect their continuity of care and oncological outcome. The long-term prevalence and clinical impact of the post-COVID-19 syndrome in patients with cancer are largely unknown.
METHODS: In this study, we describe the time course of COVID-19 sequelae in patients with non-advanced cancers enrolled in the OnCovid registry.
RESULTS: Overall, 186 patients were included, with a median observation period of 9.9 months (95%CI:8,8-11.3) post-COVID-19 resolution. After a median interval of 2.3 months post-COVID-19 (interquartile range: 1.4-3.7), 31 patients (16.6%) reported ≥1 sequelae, including respiratory complications (14, 7.6%), fatigue (13, 7.1%), neuro-cognitive sequelae (7, 3.8%). The vast majority of the patients were not vaccinated prior to COVID-19. COVID-19-related sequelae persisted in 9.8% and 8% of patients 6 and 12 months after COVID-19 resolution. Persistence of sequelae at first oncological follow-up was associated with history of complicated COVID-19 (45.2% vs 24.8%, p = 0.0223), irrespective of oncological features at COVID-19 diagnosis.
CONCLUSION: This study confirms for the first time that, in a largely unvaccinated population, post-COVID-19 syndrome can affect a significant proportion of patients with non-advanced cancer who recovered from the acute illness. COVID-19 sequelae may persist up to 12 months in some patients, highlighting the need for dedicated prevention and supportive strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:170 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 170(2022) vom: 05. Juli, Seite 10-16 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 28.06.2022 Date Revised 16.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2022.03.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340996897 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340996897 | ||
| 003 | DE-627 | ||
| 005 | 20231226010741.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2022.03.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM340996897 | ||
| 035 | |a (NLM)35576848 | ||
| 035 | |a (PII)S0959-8049(22)00163-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cortellini, Alessio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistence of long-term COVID-19 sequelae in patients with cancer |b An analysis from the OnCovid registry |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.06.2022 | ||
| 500 | |a Date Revised 16.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: A significant proportion of patients with cancer who recover from Coronavirus Disease 2019 (COVID-19) may experience COVID-19 sequelae in the early post-infection phase, which negatively affect their continuity of care and oncological outcome. The long-term prevalence and clinical impact of the post-COVID-19 syndrome in patients with cancer are largely unknown | ||
| 520 | |a METHODS: In this study, we describe the time course of COVID-19 sequelae in patients with non-advanced cancers enrolled in the OnCovid registry | ||
| 520 | |a RESULTS: Overall, 186 patients were included, with a median observation period of 9.9 months (95%CI:8,8-11.3) post-COVID-19 resolution. After a median interval of 2.3 months post-COVID-19 (interquartile range: 1.4-3.7), 31 patients (16.6%) reported ≥1 sequelae, including respiratory complications (14, 7.6%), fatigue (13, 7.1%), neuro-cognitive sequelae (7, 3.8%). The vast majority of the patients were not vaccinated prior to COVID-19. COVID-19-related sequelae persisted in 9.8% and 8% of patients 6 and 12 months after COVID-19 resolution. Persistence of sequelae at first oncological follow-up was associated with history of complicated COVID-19 (45.2% vs 24.8%, p = 0.0223), irrespective of oncological features at COVID-19 diagnosis | ||
| 520 | |a CONCLUSION: This study confirms for the first time that, in a largely unvaccinated population, post-COVID-19 syndrome can affect a significant proportion of patients with non-advanced cancer who recovered from the acute illness. COVID-19 sequelae may persist up to 12 months in some patients, highlighting the need for dedicated prevention and supportive strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Long-term | |
| 650 | 4 | |a Outcome | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Sequelae | |
| 700 | 1 | |a Salazar, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Gennari, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilar-Company, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Bower, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Bertuzzi, Alexia |e verfasserin |4 aut | |
| 700 | 1 | |a Brunet, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Lambertini, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Maluquer, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrazzoli, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Alvin Jx |e verfasserin |4 aut | |
| 700 | 1 | |a Carmona-García, MCarmen |e verfasserin |4 aut | |
| 700 | 1 | |a Newsom-Davis, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Van Hemelrijck, Mieke |e verfasserin |4 aut | |
| 700 | 1 | |a Plaja, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Zambelli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Tondini, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Generali, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Bertulli, Rossella |e verfasserin |4 aut | |
| 700 | 1 | |a Diamantis, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Uma |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzo, Gianpiero |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Tamara |e verfasserin |4 aut | |
| 700 | 1 | |a Zoratto, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Bruna, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Sureda, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Vila, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Cantini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzoni, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Grosso, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Parisi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Saponara, Maristella |e verfasserin |4 aut | |
| 700 | 1 | |a Prat, Aleix |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 700 | 0 | |a On Covid study group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 170(2022) vom: 05. Juli, Seite 10-16 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:170 |g year:2022 |g day:05 |g month:07 |g pages:10-16 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2022.03.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 170 |j 2022 |b 05 |c 07 |h 10-16 | ||